NO304380B1 - FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein - Google Patents

FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein

Info

Publication number
NO304380B1
NO304380B1 NO931680A NO931680A NO304380B1 NO 304380 B1 NO304380 B1 NO 304380B1 NO 931680 A NO931680 A NO 931680A NO 931680 A NO931680 A NO 931680A NO 304380 B1 NO304380 B1 NO 304380B1
Authority
NO
Norway
Prior art keywords
virus
proteins
hcv
hepatitis
asialoglycoprotein
Prior art date
Application number
NO931680A
Other languages
English (en)
Norwegian (no)
Other versions
NO931680L (no
NO931680D0 (no
Inventor
Frank Marcus
Kent B Thudium
Robert O Ralston
John A Hall
Barbara A Gervase
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO304380(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO931680D0 publication Critical patent/NO931680D0/no
Publication of NO931680L publication Critical patent/NO931680L/no
Publication of NO304380B1 publication Critical patent/NO304380B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO931680A 1990-11-08 1993-05-07 FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein NO304380B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61141990A 1990-11-08 1990-11-08
US61196590A 1990-11-08 1990-11-08
US75888091A 1991-09-13 1991-09-13
PCT/US1991/008272 WO1992008734A1 (en) 1990-11-08 1991-11-07 Hepatitis c virus asialoglycoproteins

Publications (3)

Publication Number Publication Date
NO931680D0 NO931680D0 (no) 1993-05-07
NO931680L NO931680L (no) 1993-06-28
NO304380B1 true NO304380B1 (no) 1998-12-07

Family

ID=27417050

Family Applications (2)

Application Number Title Priority Date Filing Date
NO931680A NO304380B1 (no) 1990-11-08 1993-05-07 FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein
NO972213A NO304381B1 (no) 1990-11-08 1997-05-14 FremgangsmÕte for fremstilling av hepatitt C-virus (HCV) og anvendelse derav i en immunoanalysemetode

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO972213A NO304381B1 (no) 1990-11-08 1997-05-14 FremgangsmÕte for fremstilling av hepatitt C-virus (HCV) og anvendelse derav i en immunoanalysemetode

Country Status (17)

Country Link
EP (2) EP0842947B2 (de)
JP (8) JPH06504431A (de)
AT (1) ATE188220T1 (de)
AU (1) AU668078B2 (de)
CA (2) CA2203443C (de)
CZ (1) CZ289006B6 (de)
DE (1) DE69131882T3 (de)
DK (2) DK0556292T4 (de)
ES (1) ES2139591T5 (de)
FI (1) FI107803B (de)
GR (1) GR3032771T3 (de)
HU (2) HU227498B1 (de)
NO (2) NO304380B1 (de)
PT (2) PT99466B (de)
RO (1) RO115446B1 (de)
SK (3) SK286106B6 (de)
WO (1) WO1992008734A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
DE69333269T2 (de) * 1992-01-31 2004-07-29 Abbott Laboratories, Abbott Park Expressionssystem in säugetieren für hcv-proteine
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
DK0721505T4 (da) 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
ES2316920T3 (es) 1994-07-29 2009-04-16 Novartis Vaccines And Diagnostics, Inc. Popipeptido truncado e2 de hepatitis c y procedimientos para obtener el mismo.
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) * 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
JP4458556B2 (ja) 1997-05-06 2010-04-28 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃ型肝炎のｅ２短縮型ポリペプチドの細胞内生成
EP0947525A1 (de) 1998-03-27 1999-10-06 Innogenetics N.V. Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ATE375804T1 (de) 2000-08-17 2007-11-15 Tripep Ab Ribavirin-enthaltende vakzine
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US20050272029A1 (en) * 2002-08-16 2005-12-08 Bertrand Saunier Hepatitis c viral-like particle purification
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
WO2009130588A2 (en) 2008-04-22 2009-10-29 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
UA41266C2 (uk) * 1990-04-04 2001-09-17 Чірон Корпорейшн Комбінація послідовностей епітопів вірусу гепатиту с (hcv), спосіб виявлення антитіл до вірусу гепатиту с (hcv), набір для виконання аналізу при виявленні антитіл до антигену гепатиту с (hcv)

Also Published As

Publication number Publication date
JP4056306B2 (ja) 2008-03-05
CZ82493A3 (en) 1994-04-13
DE69131882T3 (de) 2007-05-24
EP0556292B2 (de) 2006-11-29
SK69097A3 (en) 1997-11-05
NO972213D0 (no) 1997-05-14
DK0556292T3 (da) 2000-04-17
EP0842947B2 (de) 2009-03-18
WO1992008734A1 (en) 1992-05-29
EP0842947A2 (de) 1998-05-20
JPH06504431A (ja) 1994-05-26
NO931680L (no) 1993-06-28
EP0842947A3 (de) 2001-12-12
JPH1171395A (ja) 1999-03-16
CA2095521C (en) 2009-06-30
EP0556292B1 (de) 1999-12-29
CA2203443C (en) 2001-08-28
DE69131882D1 (en) 2000-02-03
RO115446B1 (ro) 2000-02-28
DE69131882T2 (de) 2000-05-04
EP0556292A4 (de) 1995-01-18
GR3032771T3 (en) 2000-06-30
JP2001286290A (ja) 2001-10-16
NO304381B1 (no) 1998-12-07
JP2008031181A (ja) 2008-02-14
NO972213L (no) 1997-05-14
HUT66063A (en) 1994-09-28
DK0842947T3 (da) 2004-07-26
ES2139591T3 (es) 2000-02-16
PT99466B (pt) 1999-04-30
SK44293A3 (en) 1993-08-11
ES2139591T5 (es) 2007-08-01
EP0556292A1 (de) 1993-08-25
AU668078B2 (en) 1996-04-26
SK286106B6 (sk) 2008-03-05
FI107803B (fi) 2001-10-15
SK285624B6 (sk) 2007-05-03
FI932025A (fi) 1993-06-07
AU9026791A (en) 1992-06-11
JP2003093081A (ja) 2003-04-02
CA2203443A1 (en) 1992-05-09
HU227498B1 (en) 2011-07-28
PT102022B (pt) 2000-12-29
PT102022A (pt) 1999-01-29
JP2003174875A (ja) 2003-06-24
NO931680D0 (no) 1993-05-07
FI932025A0 (fi) 1993-05-05
CA2095521A1 (en) 1992-05-09
ATE188220T1 (de) 2000-01-15
EP0842947B1 (de) 2004-04-21
SK285623B6 (sk) 2007-05-03
HU9301336D0 (en) 1993-10-28
DK0556292T4 (da) 2006-12-27
PT99466A (pt) 1992-10-30
DK0842947T4 (da) 2009-06-08
JP2005187479A (ja) 2005-07-14
JP2006219503A (ja) 2006-08-24
CZ289006B6 (cs) 2001-10-17
JP3207155B2 (ja) 2001-09-10

Similar Documents

Publication Publication Date Title
NO304380B1 (no) FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein
HU9303703D0 (en) Hepatitis c virus (hcv) polypeptides
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
HU9400741D0 (en) Immunoreactive hepatitis c virus polypeptide compositions
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
AU4446593A (en) Recombinant adenovirus vaccines
EP0216564A3 (de) Infektiöses rekombinantes Virus, dieses enthaltende Impfstoffe gegen feline Leukämie und Verfahren zu deren Herstellung
EP1471073A3 (de) Asialoglykoproteine von Hepatitis C virus
FI971702A (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
KR880003971A (ko) 재조합 바쿨로비루스 벡터로 부터 b형 간염비루스 항원의 발현
EP0385394A3 (de) Polyhedringen und gentechnologische Anwendung
PT89041A (pt) Metodo de preparacao de diagnosticos e vacinas nanbv

Legal Events

Date Code Title Description
MK1K Patent expired